Subscribe   RSS Contact Us

Doctors Weigh In on Importance of Journal Reprints, Passing H.R. 5539

Nov. 26, 2014 – Several physicians speaking at a recent meeting held in Washington, D.C., said that journal reprints, medical ... read more

Kamp: 2014 Election Results Will Have Impact on Medical Marketing

Nov. 14, 2014 – Tax reform, privacy legislation, Sunshine Act implementation and FDA/HHS enforcement and emerging policies all are issues ... read more

CMS Reinterprets Sunshine Act Final Rule to Exclude Certified CME Costs from Reporting

Nov. 3, 2014 – The certified continuing medical educations (CME) community got a “treat” on Oct. 31, when the Centers ... read more

The Elections Are Over: What Does It Mean for Healthcare?

Oct. 28, 2014 — Join us for a Webinar on Nov. 12! John Kamp, Executive Director of the Coalition for ... read more

FDA Response to MIWG Shows Willingness to Revisit Off-label Speech Policies

Oct. 27, 2014 – As members of Congress prepare legislation that may establish the conditions under which companies can share ... read more

House Legislation to Tackle Thorny Off-label Issues

Oct. 20, 2014 – It is looking like Congress may attempt to settle whether companies can speak truthfully about their ... read more

Bipartisan Bill Seeks Fix to Formalize Textbook/Reprint Sunshine Act Exclusions

Oct. 14, 2014 – After multiple efforts failed to convince the Centers for Medicare & Medicaid Services (CMS) that peer-reviewed ... read more

PhRMA, BIO, AdvaMed Tell FDA Social Media Guidance Is Lacking, Violates First Amendment

Oct. 6, 2104 – Although the FDA’s Office of Prescription Drug Promotion (OPDP) recently reopened the comment period for its ... read more

Social Media Master Class Helps Companies Navigate Compliance

Sept. 30, 2014 – Companies striving to use social media marketing both effectively and appropriately likely will benefit from a ... read more

Coalition Panel: Data Regulation Focus Shifting from Privacy to Security

Sept. 29, 2014 – The federal government’s efforts to severely limit the ability of industry to gather and use online ... read more

In Amicus Brief, PhRMA Says Off-label Case “Raises Serious First Amendment Concerns”

Sept. 19, 2014 – Stating that a whistleblower’s interpretation of the False Claims Act has “a critical flaw” because it ... read more

Pfizer’s Susman to Talk Public/Private Partnerships at Nov. 10 Coalition Briefing

Sept. 19, 2014 – Sally Susman, EVP, Corporate Affairs, Pfizer, will share her insights on the importance of public and ... read more

CMS Bombarded with Comments Calling for CME Exemption to Remain

Sept. 9, 2014 – An overwhelming majority of comments sent to the Centers for Medicare & Medicaid Services (CMS) by ... read more

Coalition Comment to CMS: Keep CME Exemption Under Sunshine Act

Sept. 2, 2014 – The Coalition for Healthcare Communication’s comment to the Centers for Medicare & Medicaid Services (CMS) asks ... read more

Open Payments Website Reopened, Dispute Period Extended and One-third of Records Withheld

Aug. 18, 2014 – The Centers for Medicare & Medicaid Services (CMS) recently announced that it had reopened its Open ... read more

Medical Groups Ask CMS to Make Changes to Sunshine Act Implementation

Doctors Recommend Fixes to CME Exemption Elimination, Educational Materials Provision Aug. 6, 2014 – More than 100 medical associations and ... read more

Doctor Tells Congress That Communication Is Hampered by FDA, CMS Practices

July 28, 2014 – FDA and Centers for Medicare & Medicaid Services (CMS) policies are barriers to ongoing evidence development ... read more

FDA Plans to Study Effect of DTC Ads on Adolescents

July 24, 2014 – A better understanding of how adolescents weigh risks and benefits in direct-to-consumer (DTC) ads is needed ... read more

Bruce Grant Urges Pharma Communicators to Recognize Their Role in Health Advances

July 23, 2014 – Although the pharmaceuticals industry has come under fire in recent years, it is important to remember ... read more

FDA Social Media Draft Guidances Answer Some Questions, Raise Others

July 21, 2014 – Although the FDA has attempted to provide some clarity on its position regarding certain social media ... read more

Kamp to Washington Post: Companies Should Be Able to Speak Truthfully About Drugs

July 14, 2014 – Drug companies should be allowed to share truthful information about the off-label uses of their drugs, ... read more

FDA Device Document Revises Mobile Medical Apps Guidance

July 1, 2014 – The FDA’s recently issued draft guidance on medical device data systems (MDDS) not only lessens the ... read more

New FDA Social Media Guidances Address Space-limited Media, Correcting Online Misinformation

June 23, 2014 – Although the two social media draft guidance documents the FDA’s Office of Prescription Drug Promotion (OPDP) ... read more

AMA House of Delegates: Revise Sunshine Act Rules on Textbook/Reprints and TOV Amount

June 12, 2014 – The American Medical Association’s (AMA’s) House of Delegates is attempting to bring some common sense to ... read more

House Committee Seeks Patient Input on Availability of Treatments

June 3, 2014 – The House Energy and Commerce Committee is seeking public comments from patients, providers and other stakeholders ... read more

FDA To Study Viewers’ Responses to DTC Ad Risk Information

May 29, 2014 – The FDA announced May 28 in the Federal Register that it plans to conduct an eye ... read more

WLF: FDA’s Revised Reprint Draft Guidance Violates Injunction and First Amendment

May 19, 2014 – In May 15 comments to the FDA regarding its draft guidance on reprint practices for articles ... read more

CHC Comment to FDA: Less Is More in DTC TV Ads

May 2, 2014 – The Coalition for Healthcare Communication believes that “shorter, simpler disclosures are most likely to lead to ... read more

FDA Willing to “Re-examine” Off-label Policies in Light of First Amendment Rulings

April 28, 2014 – The FDA is not taking lightly industry’s concerns that its existing off-label policies are not in ... read more

New Tax Reform Legislation Includes Limit on Ad Tax Deductions

Feb. 27, 2014 – As expected, tax reform legislation introduced yesterday by Senate Ways and Means Committee Chairman Dave Camp ... read more

FDA Is Considering Shorter List of Risks in DTC TV Ad Major Statement

Feb. 17, 2014 – In recognition that the stream of risks currently disclosed on direct-to-consumer (DTC) television ads may be ... read more

Caronia Decision One Year Later: Off-label Change May Be Slow, But It’s Brewing

Jan. 27, 2014 – Although FDA officials have treated the U.S. Court of Appeals for the Second Circuit decision in ... read more

Coalition Calls on Senators to Reject Tax on Advertising

Dec. 16, 2013 – Today the Coalition for Healthcare Communication sent a letter to U.S. Senators and Members of the ... read more

OPDP Sends Warning Letter Based on Statements Made on Fast Money TV Show

Nov. 11, 2013 – The FDA Office of Prescription Drug Promotion’s (OPDP’s) recent enforcement actions – four Untitled Letters and ... read more

Physician Organizations, Medical Societies Implore HHS to Reverse Policy on Reprints and Textbooks

Oct. 28, 2013 – On Monday, 33 physician organizations and 41 national and state medical societies sent a letter to ... read more

MIWG Asks FDA to Clarify Position Regarding Manufacturer Dissemination of New Use Information

Sept. 16, 2013 – The Medical Information Working Group (MIWG), a coalition of medical product manufacturers seeking to improve the ... read more

Previous Next

ISMPP Offers Guidance on Value of Publication Support in Sunshine Act “Suggestions Document”

Aug. 19, 2013 – Companies struggling to define and place a value on the publication support they provide to physicians authoring medical publication submissions under the Sunshine Act will find some reasonable advice in a “suggestions document” recently published by the International Society for Medical Publication Professionals (ISMPP).

“Our action here was to understand and interpret this provision of the final rule and respond to questions from our members about it,” said Bob Norris, ISMPP founding member and past president, and founder of CHC Group, who served on the ISMPP Task Force that authored the document. “There is so little direct guidance from the Centers for Medicare & Medicaid Services (CMS) on how to define transfers of value for this practice, so we wanted to step in to fill that gap,” he said.

The ISMPP Task Force document – which is designed to help entities determine the value of publication support that is transferred and how to apportion that value among covered recipients (CRs) – is based on a review of the Physician Payment Transparency Program final rule, internal discussions, and meetings with CMS representatives and stakeholders in the medical publications space.

Norris told the Coalition for Healthcare Communication that informal meetings with CMS were “very constructive in determining the parameters” of the guidance, but that CMS’ direct responses to questions on this issue sent to the agency through its Web site “will be the ultimate answer.”

Parsing the final rule’s mandate that transfers of value (TOV) made by applicable manufacturers (AMs) to CRs be reported under the Sunshine Act, the ISMPP Task Force considers the TOV to be “any support provided to CR authors for publication that will be submitted, or is intended to be submitted, to a scientific or medical journal, or provided to authors/speakers for submission to or presentation at a professional congress.”

What to Report

According to the Task Force, AMs should consider the following activities when determining what comprises publication support:  

  • Medical writing and editing under the direction of the author(s)
  • Statistical support performed specifically for the publication
  • Literature searches and provision of references
  • Graphic support
  • Securing permissions/permission fees
  • Journal submission
  • Submission and publication fees (includes fees associated with open-access journals)
  • Direct costs for travel, meals, and other expenses associated with performance of work associated with publications (e.g., congress attendance; publication steering committee).

ISMPP also suggests that publication support activities “are reportable regardless of whether they are included in or outside of a research contract,” although they may be reported using different templates (General Payments, Physician Ownership or Research Payments).

Allocating and Assigning Value

For many manufacturers, the trickiest reporting element is how to place a value on the publication support they provide and allocate it among authors. Norris noted that this was the “diciest question” the ISMPP Task Force had to tackle, and that although the group “tried to come up with a definitive ‘this is how you do it’ approach,” it saw the need for several options.

The ISMPP Task Force states in the document that manufacturers should “individually determine the method for allocating specific TOV to each CR who was provided publication support.” The defining question here, according to the ISMPP, is: “What is the value of specific tasks that the authors would have had to perform or secure for themselves if the AM had not provided publication support?”

To help answer that question, the Task Force provides sorted lists of publication support activities that fall into two categories: (1) “Work That an Author Would Most Likely Do” (which should be included in the value calculation); and (2) “Work That an Author Would Most Likely Not Do” (which should not be included in the value assessment).

When assigning the calculated value of the support to authors, the ISMPP Task Force suggests two approaches for consideration and comments both that companies also may have other interpretations and that individuals should “seek internal legal and policy guidance on interpretation and application of the law to their company.”

The first approach, a “project-by-project determination,” takes the total cost of the publication support and divides it by the number of authors associated with the publication. The document includes an example of this scenario:

“A primary manuscript costs $30,000. There are a total of 6 authors; 3 authors are US CRs, 2 authors reside and practice outside of the US and do not hold current US licenses, and 1 is an AM employee. For the purpose of this example, it is determined that 30% ($9,000) of the total cost is for non-content-development activities. The total value of the content-development activities is $21,000; the reportable TOV per author for the development of the manuscript is $3,500 ($21,000/6) TOVs are reported for the 3 US authors (3 x $3,500).”

A second assignment approach described in the ISMPP document uses “average fair market value” (FMV) as the sum of average costs associated with the specific type of publication, with the same FMV amount to be reported per author. So, if the average cost of a manuscript for Company X is determined to be $28,000 with an average of 6 authors, the document states, after you have subtracted the average non-content-development related costs of 27%, the content-related costs of the work are $20,440 and the reportable per-author FMV is $3,406 per manuscript ($20,440/6).

Whichever approach is used, the Task Force underscores the importance of submitting an assumptions document to CMS describing the methodology used to determine reportable costs. “The assumptions document is an integral part of the report, especially due to the lack of CMS guidance,” Norris said, “as long as you are transparent and list how you allocate value.” He also noted that although there may be some justifiable outliers, “Using the same methodology across the board is more defendable.”

Norris added that he hopes there will not be “unintended consequences” to the mandated reporting of publication support. “Although this support has value, doctors are not receiving a penny; the support only helps get important data published quickly so it can change clinical practice as appropriate,” he said. “If doctors back off from receiving this support because they don’t want that TOV listed next to their names, the process of getting those data out without assistance will take much longer, and that will affect patients.”

Reporting under the Sunshine Act began on Aug. 1.